AURKA and rhabdomyosarcoma: When AURKA inhibitor alisertib is combined with navitoclax (a Bcl2 inhibitor) in experiments involving fusion-positive rhabdomyosarcoma cell lines and patient-derived xenografts, a potent synergy emerges.